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egenerative (or primary) mitral regurgitation (MR) is the most prevalent valvular heart disease, with an estimated prevalence of 2% of the general population. 1 The most frequent form of degenerative MR is mitral valve prolapse caused by elongation or rupture of tendinous chords. Factors considered in the clinical decision making of patients with mitral valve prolapse include the impact of MR severity on symptoms, left ventricular (LV) dimensions and function, left atrial dilation, the presence of atrial fibrillation and pulmonary hypertension, and the possibility of performing a durable mitral valve repair. 2 Transthoracic echocardiography and transesophageal echocardiography remain the most common methods to evaluate the severity and mechanism of MR, LV dimensions and function, left atrial volume, and presence of pulmonary hypertension. Over the past 15 years, cardiovascular magnetic resonance (CMR) has gained acceptance for the assessment of patients with MR, providing information on MR severity and accurate measurements of LV or left atrial dimensions and function. However, echocardiography and CMR differ in the manner in which they quantify the severity of MR.
Echocardiographic determinations of the severity of MR rely on color Doppler visualization of the regurgitant jet area, estimation of the regurgitant volume by subtracting the forward flow across the aortic valve from that occurring across the mitral valve, quantification of pulmonary vein flow profiles, or measurement of the mitral valve regurgitant orifice area, regurgitant volume, and regurgitant fraction with the proximal isovelocity surface area (PISA). 3 The PISA method is based on identification of differences in regurgitant blood flow velocity that accelerates through the regurgitant orifice. However, the PISA method is less accurate in eccentric regurgitant jets and noncircular orifices or when the blood flow across the leaking valve is not holosystolic. In addition, the PISA method cannot be applied when multiple regurgitant jets are present. Miscalculation of the effective regurgitant orifice area of 10% to 25% by the PISA method has been reported among expert observers. 4 Direct planimetry of the regurgitant orifice area with 3-dimensional echocardiographic techniques has improved the accuracy of quantifying the regurgitant volume and has shown better agreement with CMR. 5, 6 CMR techniques quantify the severity of MR through direct measurement of the mitral regurgitant volume and fraction using phase-contrast techniques. Mitral regurgitant volume and regurgitant fraction can be quantified with phase-contrast methods. The first method subtracts the aortic forward stroke volume from the LV stroke volume obtained by planimetry of LV short-axis cine images. It is important to note that this methodology is not applicable when aortic regurgitation coexists. The second method uses the phase-contrast method in isolation and directly measures the mitral regurgitant flow at the mitral valve. CMR flow measurements have been validated with in vitro and in vivo measurements. 7 Compared with echocardiography, CMR measurements are less influenced by geometric assumptions, jet direction, or multiple regurgitant jets and exhibit relatively low interobserver variability. However, few studies have provided specific CMR thresholds of regurgitant volume and regurgitant fraction to define severe MR. 8 Accordingly, the CMR thresholds that define severe primary MR are the same as those used with echocardiography: regurgitant volume ≥60 mL per beat and regurgitant fraction ≥50%.
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At present, CMR is indicated in the assessment of MR when the echocardiographic images are suboptimal or when there is disagreement between the calculated quantitative parameters of MR and symptoms or other measured parameters such as grade of LV dilation and dysfunction, left atrial dilation, and pulmonary hypertension. However, it is important to note that the agreement between 2-dimensional echocardiography and CMR in evaluating primary MR severity is modest. 5, 6, 9 In this issue of Circulation, Penicka and colleagues provide additional data on the agreement between echocardiography and CMR for grading primary MR severity. 10 Two-dimensional transthoracic and transesophageal echocardiography and CMR were performed in 258 asymptomatic patients with moderate or severe primary MR (25% with fail leaflet and 75% with prolapse) and an LV ejection fraction >60%. The severity of MR was graded according to current recommended methodologies, as previously described. The mean regurgitant volume obtained with the echocardiographic PISA method was 17.1 mL larger than the regurgitant volume calculated with CMR. Concordant grading of primary MR with both techniques was reported in 197 patients (76%; 135 with moderate and 62 with severe MR). Among the remaining 61 patients (24%) with discordant grading of MR between echocardiography and CMR, echocardiography assigned a higher grade of MR in 62% of patients. The overall agreement between echocardiography and CMR to differentiate between severe and nonsevere MR was modest (κ=0.48). Latesystolic and multiple regurgitant jets were the main determinants of poor agreement between techniques.
Furthermore, the present study provides important information on the discriminative power of echocardiography and CMR to predict the occurrence of all-cause mortality, the development of a Class I or IIa indication for mitral valve surgery, or the combination of both. 10 As expected, the event rates were higher among patients with concordant severe MR based on echocardiography and CMR versus patients with concordant moderate MR. Patients with discordant MR severity, with severe MR on CMR but moderate MR by echocardiography, experienced event rates similar to those of individuals with concordant severe MR (indication for surgery, 52% versus 50%; all-cause mortality, 22% versus 27%, respectively), whereas patients with moderate MR by CMR and severe MR by echocardiography experienced outcomes similar to those of individuals with concordant moderate MR (indication for surgery, 13% versus 15%; all-cause mortality, 11% versus 9%, respectively).
CMR measures of mitral regurgitant volume demonstrated the largest area under the receiver-operating characteristic curve to predict the combined end point of mortality or indication for surgery in this population of individuals with asymptomatic primary MR. A CMRderived mitral regurgitant volume of ≥50 mL yielded a sensitivity and specificity of 77% and 78%, respectively, for predicting this combined end point. These results are similar to those reported by Myerson et al 8 in 109 asymptomatic patients with moderate or severe MR.
The importance of these results relies on the study population, asymptomatic patients with MR, in whom the timing for intervention depends on the hemodynamic consequences of MR and the expertise of the surgical team to perform durable mitral valve repair. 2 In this study, 38 patients with severe MR on echocardiography would have been reclassified as nonsevere with CMR and could have been managed medically. In contrast, 23 patients could have been referred earlier to surgery on the basis of CMR grading. Therefore, the present results endorse current recommendations on the use of CMR in MR severity assessment. 3 In summary, both echocardiography and CMR can be used to assess the presence, mechanism, and severity of MR, along with the impact of the MR on both atrial and ventricular structure and function. The results of the present study support the use of CMR to help determine the optimal timing for surgical mitral valve repair. Future studies are needed to determine whether early mitral valve repair in patients with severe primary MR who are asymptomatic and do not have Class I indications for surgery improves outcomes related to survival, preservation of LV performance, and freedom from the development of atrial fibrillation. CMR may play an important role in those studies because this imaging technique permits comprehensive and accurate assessment of MR severity, chamber quantification (dimensions and function), and structural assessment (myocardial fibrosis).
